Improving the Bioprocessing of ADEPT Fusion Proteins using Ultra Scale-Down Techniques

Today with the advancement of modern medicine we are increasingly facing an aging community with a variety of complicated disease like the various forms of Cancer. Although man made synthetic chemicals can treat simple diseases, scientists predict that a new range of therapeutics containing antibody fragments and fusions proteins, may be important because of their ability to target specific sites. The new family of complicated biopharmaceuticals, such as fusions of larger molecules are more likely to be fragile and delicate to the unforgiving large-scale manufacturing environments. So new research needs to be conducted into where the damage may be occurring and how to stop it from happening.